References
- Werner AA. The male climacteric. J Am Med Assoc 1939;112:1441–3
- Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 1999;84:3666–72
- Bremner WJ, Vitiello MV, Primz PN. Loss of circadian rhythmicity in blood testosterone levels with aging in normal man. J Clin Endocrinol Metab 1983;56:1278–81
- Morley JE, Kaiser F, Raum WJ, et al. Potentially predictive and manipulable blood serum correlates of aging in the healthy male: progressive decrease in bioavailable testosterone, dehydroepiandrosterone sulfate, and the ratio of insulin like growth factor 1 to growth hormone. Proc Natl Acad Sci USA 1997; 94:7537–42
- Gray A, Feldman A, McKinlay JB, et al. Age, disease, and changing sex hormone levels in middle-aged men: results of the Massachusetts Male Aging Study. J Clin Endocrinol Metab 1991;73:1016–25
- Schow DA, Redmon B, Pryor JL. Male meno- pause. Postgrad Med 1997;101:62–79
- Morley JE, Charlton E, Patrick P, et al. Validation of a screening questionnaire for androgen defi- ciency in aging male (ADAM). Presented at Endo- crine Society Meeting, June 1998
- Heinemann LAJ, Zimmermann T, Vermeulen A, et al. A new ‘aging males’ symptoms’ rating scale. Aging Male 1999;2:105–14
- Tremblay RR, Morales A. Canadian practice recommendations for screening, monitoring and treating men affected by andropause or partial androgen deficiency. Aging Male 1998;1:213–18
- Gooren LJG. The age-related decline of androgen levels in men: clinically significant? Br J Urol 1996; 78:763–8
- Phillips GB, Pinkernerll BH, Jing TY. The associa- tion between hypotestosteronemia and coronary artery disease in men. Arterioscler Thromb 1994; 14:701–6
- Gooren LJG. A ten-year safety study of the oral androgen testosterone undecanoate. J Androl 1994; 15:212–15